Compare BLKB & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | SDGR |
|---|---|---|
| Founded | 1981 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2004 | 2020 |
| Metric | BLKB | SDGR |
|---|---|---|
| Price | $49.04 | $26.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $56.25 | $33.57 |
| AVG Volume (30 Days) | 362.5K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | 45.14 |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $4.68 | N/A |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $25.58 | $10.95 |
| 52 Week High | $64.84 | $34.00 |
| Indicator | BLKB | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 46.52 |
| Support Level | $45.72 | $11.27 |
| Resistance Level | $50.76 | $32.61 |
| Average True Range (ATR) | 1.71 | 2.47 |
| MACD | -0.88 | -0.47 |
| Stochastic Oscillator | 0.00 | 14.40 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.